Trial · NCT03377803
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS) | VP-102 | 81 | Participants | ||
| Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS) | Placebo | 15 | Participants | ||
| Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit | VP-102 | 42 | Participants | ||
| Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit | Placebo | 5 | Participants | ||
| Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit | VP-102 | 19 | Participants | ||
| Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit | Placebo | 4 | Participants | ||
| Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit | VP-102 | 8 | Participants | ||
| Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit | Placebo | 2 | Participants | ||
Change From Baseline of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age | VP-102 | Day 21 | -1.0 | Standard Deviation 3.31 | score on a scale |
Change From Baseline of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age | Placebo | Day 21 | -1.2 | Standard Deviation 3.17 | score on a scale |
Change From Baseline of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age | VP-102 | Day 42 | -1.5 | Standard Deviation 3.20 | score on a scale |
Change From Baseline of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age | Placebo | Day 42 | -1.4 | Standard Deviation 2.82 | score on a scale |
Change From Baseline of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age | VP-102 | Day 63 | -2.0 | Standard Deviation 3.28 | score on a scale |
Change From Baseline of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age | Placebo | Day 63 | -1.6 | Standard Deviation 3.04 | score on a scale |
Change From Baseline of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age | VP-102 | Day 84 (EOS) | -2.1 | Standard Deviation 3.34 | score on a scale |
Change From Baseline of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age | Placebo | Day 84 (EOS) | -1.9 | Standard Deviation 3.35 | score on a scale |
| Percent Change of All Treatable Molluscum Lesions (Baseline and New) From Baseline at the EOS Visit | VP-102 | -83.3 | Standard Deviation 43.13 | percentage change from Baseline | |
| Percent Change of All Treatable Molluscum Lesions (Baseline and New) From Baseline at the EOS Visit | Placebo | -19.1 | Standard Deviation 108.38 | percentage change from Baseline | |
| Change From Baseline in the Number of Treatable Molluscum Lesions (Baseline and New) at the EOS Visit | VP-102 | -17.1 | Standard Deviation 22.87 | change in wart count from baseline | |
| Change From Baseline in the Number of Treatable Molluscum Lesions (Baseline and New) at the EOS Visit | Placebo | -10.9 | Standard Deviation 20.14 | change in wart count from baseline |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03377803/results